Literature DB >> 11107128

Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis.

S Hopkins-Donaldson1, J L Bodmer, K B Bourloud, C B Brognara, J Tschopp, N Gross.   

Abstract

UNLABELLED: Background and Procedures NB-derived cell lines were tested for their sensitivity to apoptosis induced by the tumor-selective apoptotic ligand TRAIL. Noninvasive S-type cell lines are highly sensitive to TRAIL, whereas invasive N-type cell lines are resistant.
RESULTS: Although both S- and N-type cell lines express TRAIL-R2, FADD, and caspases-3 and -10, only S-type cells express caspase-8. Reduced levels of caspase-8 protein were also observed in a stage IV NB tumor when compared to a ganglioneuroma. The caspase-8 gene is not deleted in either N-type NB cell lines or high-stage tumors, and expression can be induced by demethylation.
CONCLUSIONS: Therefore, caspase-8 expression is silenced in malignant NB, which correlates to tumor severity and resistance to TRAIL-induced apoptosis. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11107128     DOI: 10.1002/1096-911x(20001201)35:6<608::aid-mpo25>3.0.co;2-u

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  10 in total

1.  A classification-based machine learning approach for the analysis of genome-wide expression data.

Authors:  James Lyons-Weiler; Satish Patel; Soumyaroop Bhattacharya
Journal:  Genome Res       Date:  2003-03       Impact factor: 9.043

2.  Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.

Authors:  Rani E George; Jill M Lahti; Peter C Adamson; Kejin Zhu; David Finkelstein; A Mark Ingle; Joel M Reid; Mark Krailo; Donna Neuberg; Susan M Blaney; Lisa Diller
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

Review 3.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

Review 4.  The connections between neural crest development and neuroblastoma.

Authors:  Manrong Jiang; Jennifer Stanke; Jill M Lahti
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

5.  Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.

Authors:  Motoo Nagane; Saki Shimizu; Eiji Mori; Shiro Kataoka; Yoshiaki Shiokawa
Journal:  Neuro Oncol       Date:  2010-02-11       Impact factor: 12.300

6.  Menin-mediated caspase 8 expression in suppressing multiple endocrine neoplasia type 1.

Authors:  Ping La; Yuqing Yang; Satyajit K Karnik; Albert C Silva; Robert W Schnepp; Seung K Kim; Xianxin Hua
Journal:  J Biol Chem       Date:  2007-08-31       Impact factor: 5.157

7.  Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells.

Authors:  Manrong Jiang; Kejin Zhu; Jose Grenet; Jill M Lahti
Journal:  Biochim Biophys Acta       Date:  2008-03-10

8.  Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.

Authors:  F Condorelli; I Gnemmi; A Vallario; A A Genazzani; P L Canonico
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

9.  Chlorella vulgaris triggers apoptosis in hepatocarcinogenesis-induced rats.

Authors:  Emey Suhana Mohd Azamai; Suhaniza Sulaiman; Shafina Hanim Mohd Habib; Mee Lee Looi; Srijit Das; Nor Aini Abdul Hamid; Wan Zurinah Wan Ngah; Yasmin Anum Mohd Yusof
Journal:  J Zhejiang Univ Sci B       Date:  2009-01       Impact factor: 3.066

10.  Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells.

Authors:  David J Taylor; Christine E Parsons; Haiyong Han; Arul Jayaraman; Kaushal Rege
Journal:  BMC Cancer       Date:  2011-11-01       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.